التفاصيل البيبلوغرافية
| العنوان: |
Assessment of Clinical Outcomes in Patients With Osteoarthritis: Analysis From the UK Medical Cannabis Registry. |
| المؤلفون: |
Francis, Ann, Erridge, Simon, Holvey, Carl, Coomber, Ross, Holden, Wendy, Rucker, James, Platt, Michael, Sodergren, Mikael |
| المصدر: |
Journal of Pain & Palliative Care Pharmacotherapy; Jun2024, Vol. 38 Issue 2, p103-116, 14p |
| مصطلحات موضوعية: |
CANNABIDIOL, MEDICAL marijuana, STATISTICAL correlation, PATIENT safety, CHRONIC pain, QUESTIONNAIRES, SCIENTIFIC observation, TREATMENT effectiveness, BRIEF Pain Inventory, DESCRIPTIVE statistics, LONGITUDINAL method, OSTEOARTHRITIS, RESEARCH, PAIN management, HEALTH outcome assessment, COMPARATIVE studies, PATIENT aftercare, THERAPEUTICS, EVALUATION |
| مصطلحات جغرافية: |
UNITED Kingdom |
| مستخلص: |
Osteoarthritis accounts for 0.6% of disability-adjusted life years globally. There is a paucity of research focused on cannabis-based medicinal products (CBMPs) for osteoarthritic chronic pain management. This study aims to assess changes in validated patient-reported outcome measures (PROMs) and CBMP clinical safety in patients with osteoarthritis. A prospective case series from the UK Medical Cannabis Registry was analyzed. Primary outcomes were changes in the Brief Pain Inventory (BPI), McGill Pain Questionnaire (MPQ2), EQ-5D-5L, Generalized Anxiety Disorder-7 (GAD-7) questionnaire, and Single-Item Sleep Quality Scale (SQS) at 1-, 3-, 6-, and 12-month follow-ups from baseline. Common Terminology Criteria for Adverse Events v.4.0 was used for adverse event (AE) analysis. Statistical significance was defined as p < 0.050. Seventy-seven patients met inclusion criteria. CBMP initiation correlated with BPI pain severity (p = 0.004), pain interference (p = 0.005), and MPQ2 (p = 0.017) improvements at all follow-ups compared to baseline. There were improvements in the EQ-5D-5L index (p = 0.026), SQS (p < 0.001), and GAD-7 (p = 0.038) up to 6 and 3 months, respectively. Seventeen participants (22.08%) recorded 76 mild AEs (34.86%), 104 moderate AEs (47.71%), and 38 severe AEs (17.43%). Though causality cannot be assumed in this observational study, results support development of randomized control trials for osteoarthritis pain management with CBMPs. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Pain & Palliative Care Pharmacotherapy is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
